Skip to content

Women's Wellness after Cancer Program

The Women’s Wellness after Cancer Program: A National Multisite Randomised Clinical Trial of an E-Health Enables Lifestyle Modification Intervention to Improve the Health and Wellness of Women after Cancer Treatment.

Status
Completed
Phases
Unknown
Study type
Interventional
Source
ANZCTR
Registry ID
ACTRN12614000800628
Acronym
WWACP
Enrollment
351
Registered
2014-07-28
Start date
2014-10-21
Completion date
2016-03-31
Last updated
2020-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

The Women's Wellness after Cancer Program (WWACP) will determine the effect of a 12 week, e-health enabled program, on the health-related quality of life (HRQoL) in women who have received treatment for breast, blood, or gynecological cancer. Those who are eligible to join the study are women aged 18 years or above who have completed surgery, chemotherapy, and / or radiotherapy within the past 12 months. Participants in this study are randomly allocated (by chance) to one of two groups. Participants in the intervention group are are given access to an e-health enabled, structured health promotion program which will include an interactive iBook and website containing health information, planning and goal setting, and three personal conferences with a nurse via video-conferencing. Participants in the control group will receive usual care which includes only that information and support that is given as part of usual practice through their usual clinic visits. Participants from both groups will be asked to complete questionnaires before the program begins (0 weeks), at 12 weeks, and again at 24 weeks, in order to determine the effect of the program on HRQoL

Interventions

The intervention is a 12 week, e-health enabled, structured health promotion intervention targeted at improving health related quality of life and reducing chronic disease risk factors in women previously treated for haematological, breast and gynaecological cancers. All women in the intervention arm will receive health education material, including a Program Journal (in the form of an interactive iBook), and access to an interactive web interface. The iBook will encourage women to bring togethe

The intervention is a 12 week, e-health enabled, structured health promotion intervention targeted at improving health related quality of life and reducing chronic disease risk factors in women previously treated for haematological, breast and gynaecological cancers. All women in the intervention arm will receive health education material, including a Program Journal (in the form of an interactive iBook), and access to an interactive web interface. The iBook will encourage women to bring together the various components of the health education provided and incorporate them into their lives over a 12-week period. The iBook includes a weekly exercise planner, where women are encouraged to plan ahead for their exercise in the following week. Participants will receive access to self-directed resources (via the website) and personal consultations (via videoconference) with a nurse. Three individual, virtual 30 minute consultations at 0, 6 and 12 weeks will be provided by a registered nurse trained in the intervention.

Sponsors

Queensland University of Technology
Lead SponsorUniversity

Study design

Allocation
Randomised controlled trial
Intervention model
Parallel
Primary purpose
Prevention
Masking
Blinded (masking used) (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years
Healthy volunteers
No

Inclusion criteria

(1) Completed chemotherapy (primary or adjuvant) and/or radiotherapy within the past 24 months for breast, blood and/or gynecological cancer (2) Able to speak and read Level 10 English. Participants on maintenance endocrine treatments will be included.

Exclusion criteria

(1) Metastatic or advanced cancer and inoperable or active loco-regional disease (2) Any clinical, cognitive or psychiatric contraindication identified by treating staff.

Outcome results

None listed

Source: ANZCTR · Data processed: Mar 11, 2026